
1 of 19

Document: SMF-001 Vers. 13

Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017



Certificate No: IT-API/77/H/2014

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC

The competent authority of staly confirms the following: The manufacturer PROCOS S.P.A.

Site address Via Matteotti, 249 - 28062 CAMERI (NO)

Is an active substance manufacturer that has been inspected in accordance with Art. 1.11(1) of Directive 2001/83/EC transposed in the following national legislation: **D.L. n. 219 of 24th April 2006** art. **53**

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 10/31/2013, it is considered that it complies with the Good Manufacturing Practice requirements referred to in the principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection, after which time the issuing authority should be consulted. The authenticity of this certificate may be verified with the issuing authority.

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+39065978439 Fax+390659784312
website: www.agenziafarnaco.it
SIS: 1749



Part 2

Name and address of the site: PROCOS S.P.A. - Via Matteotti, 249, 28062 CAMERI (NO)

Name of the active Substances manufactured or imported:

ALVERINE CITRATE

CLOFEDANOL HYDROCHLORIDE CHLOROPYRAMINE HYDROCHLORIDE DALTAMPRIDINE

DROFENINE HYDROCHLORIDE

FELBAMATE

PHENELZINE SULFATE

PHENYLTOLOXAMINE CITRATE

GUANFACINE HYDROCHLORIDE

ILOPERIDONE

ISOPROPAMIDE IODIDE

LABETALOL HYDROCHLORIDE

LEVOSULPIRIOE

LURASIDONE HYDROCHLORIDE

MEMANTINE HYDROCHLORIDE

METHOXYPHENAMINE HYDROCHLORIDE

NAFTIDROFURYL HYDROGEN OXALATE

NAFTOPIDIL

ORPHENADRINE CITRATE

ORPHENADRINE HYDROCHLORIDE

PYRIDOSTIGMINE BROMIDE

PROPAFENONE HYDRÓCHLÓRIDE

RANOLAZINE

SIVELESTAT SODIUM TETRAHYDRATE

TROSPIUM CHLORIDE

TUAMINOHEPTANE SULFATE

AIFA Italian Medicines Agency
Manufacturing Authorization Offico
Via del Tritone, n° 181 - 00187 ROMA (ITALY)

Fax +390659784312 website: yyyw.agenziafarmaco.it SIS: 1749

PC GMP

.

Document: SMF-001 Vers. 13 Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017

Agenzia Stuliura del Farmaco AlÆ

3 - Manufact	uring Operations - Active Substances
ALVERINE CIT	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
L	Crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quality Control lesting
	3.6.1. Physical / Chemical testing

3 - Manuf	acturing Operations - Active Substances
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1.
	3.1.2.
	3.1.3.
3.5	Généta Finishing Steps
	3.5.1.
3 %	
\$ \`@\	3.5.2.
劉 [4]	
₩9.	3.5.3.
₿₽ 	

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.arcnizlafarmaco.it
SIS: 1749

Agenzia Staliana del Fauriaco Al-A

	* 25 5 4
3,6	Quality Control Testing
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3.6.1.
1	

3 - Manufacturing Operations - Active Substances		
CLOFEDANOL HYDROCHLORIDE		
3.1 Manu	facture of Active Substance by Chemical Synthesis	
3.1.1.	Manufacture of active substance intermediates	
3.1.2.	Manufacture of crude active substance	
3.1.3.	Salt formation / Purification steps:	
	Crystallisation	
3.5 Gener	al Finishing Steps	
3.5.1.	Physical processing steps	
	Drying, sieving, milling/micronisation	
	Primary Packaging (enclosing / scaling the active substance within a	
	ging material which is in direct contact with the substance)	
	Secondary Packaging (placing the sealed primary package within an	
outer	packaging material or container. This also includes any labelling of the	
mater	ial which could be used for identification or traceability (lot	
numb	ering) of the active substance)	
401-47-4	y Control Testing	
3.6.1.	Physical / Chemical testing	

		perations - Active Substances HYDROCHLORIDE
		acture of Active Substance by Chemical Synthesis
	3.1.1.	Manufacture of active substance intermediates
	3.1.2.	Manufacture of crude active substance
	3.1.3.	Salt formation / Purification steps:
\		Crystallisation
3.5	Genera	il Finishing Steps
	3.5.1.	Physical processing steps
		Drying, sieving, milling/micronisation

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, nº 181 - 00187 ROMA (ITALY)
Tel.+390859784489 Fax+390869784312
website: www.agenziafattus.acc.it
SIS: 1749

Document: SMF-001 Vers. 13

Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017



AIA

3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

6.6 Quality Control Testing

3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances DALFAMPRIDINE

- Manufacture of Active Substance by Chemical Synthesis
 - 3.1.1. Manufacture of active substance intermediates
 - **3.1.2.** Manufacture of crude active substance
 - **3.1.3.** Salt formation / Purification steps: Crystallisation
- 3.5 General Finishing Steps
- 3.5.1. Physical processing steps
 - Drying, sleving, milling/micronisation
 - **3.5.2.** Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
 - 3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
- 3.6 Quality Control Testing
 - 3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances

Manufacture of Active Substance by Chemical Synthesis

3.1.1.

3.1.2.

2 1 2

AIFA Italian Modicines Agency
Manufacturing Authorization Office
Via del Tritone, nº 181 - 00187 ROMA (ITALY)
Tel ÷389059784488 Fax ÷390659784312
website: www.agenziefannaco.it
SIS: 1749

Ligenzia Staliana del Farmuce AVA

3.5	General Finishing Steps
1	3.5.1.
	3.5.2.
	3.5.3.
•	
3.6	Quality Control Testing
	3.6.1.

3 - Manufacturing Operations - Active Substances		
DROFENINE HYDRO		
3.1 , Manu	acture of Active Substance by Chemical Synthesis	
3.1.1.	Manufacture of active substance intermediates	
	Manufacture of crude active substance	
3.1.3.	Salt formation / Purification steps:	
	Crystallisation	
3.5 Gener	al Finishing Steps	
3.5.1.	Physical processing steps	
	Drying, sieving, milling/micronisation	
3.5.2.	Primary Packaging (enclosing / sealing the active substance within a	
	ging material which is in direct contact with the substance)	
3.5.3.	Secondary Packaging (placing the scaled primary package within an	
	packaging material or container. This also includes any labelling of the	
mater	ial which could be used for identification or traceability (lot	
aumbi	ering) of the active substance)	
3.6 Qualit	y Control Testing	
3.6.1.	Physical / Chemical testing	

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. >3906978489 Fax +390669784312
website: www.agenziafarmaco.it
SIS: 1749

100 m



3 - Manufaci FELBAMATE	turing Operations - Active Substances
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances		
PHENELZINE SULFA	TE	
3.1 Manu	facture of Active Substance by Chemical Synthesis	
3.1.1.	Manufacture of active substance intermediates	
3.1.2.	Manufacture of crude active substance	
3.1.3.	Salt formation / Purification steps:	
	Crystallisation	
3.5 Gene	al Finishing Steps	
3.5.1.	Physical processing steps	
<u> </u>	Drying, sieving, milling/micronisation	
	Primary Packaging (enclosing / sealing the active substance within a	
packa	ging material which is in direct contact with the substance)	
	Secondary Packaging (placing the sealed primary package within an	
√ outer	packaging material or container. This also includes any labelling of the	
mater	rial which could be used for identification or traceability (lot	
numb	ering) of the active substance)	

AIFA Italian Medicines Agericy
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.÷390659784489 Fax ÷390659784312
wobsite: <u>www.agenzia6armaco.it</u>
SIS : 1749



3.6 Qua	lity Control Testing
3.6.	1. Physical / Chemical testing

3 - Manufa	cturing Operations - Active Substances		
PHENYLTOLOXAMINE CITRATE			
3.1	Manufacture of Active Substance by Chemical Synthesis		
	3.1.1. Manufacture of active substance intermediates		
	3.1.2. Manufacture of crude active substance		
	3.1.3. Salt formation / Purification steps:		
	Crystallisation		
3.5	General Finishing Steps		
	3.5.1. Physical processing steps		
	Drying, sieving, milling/micronisation		
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a		
	packaging material which is in direct contact with the substance)		
	3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the		
	material which could be used for identification or traceability (lot		
	numbering) of the active substance)		
3.6	Quality Control Testing		
	3.6.1. Physical / Chemical testing		

3 - Manufacturing Operations - Active Substances GUANFACINE HYDROCHLORIDE	
3.1 (10)	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
•	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps
]	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)


AIFA Italian Medicinos Agoncy Manufecturing Authorization Office Via del Tritone, nº 181 - 00187 ROMA (ITALY) Tel.+390659784489 Fax +390659784312 website: www.agenziafarmaco.it SIS: 1749

PC GMP

Document: SMF-001 Vers. 13

Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017





AIA

3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

Quality Control (esting

3.6.1. Physical / Chemical testing

3 - Manufacti	iring Operations - Active Substances
ILOPERIDONE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quality Control Testing

3 - Manufacturing Operations - Active Substances ISOPROPAMIDE IODIDE

3.6.1. Physical / Chemical testing



Manufacture of Active Substance by Chemical Synthesis

- 3.1.1. Manufacture of active substance intermediates
- 3.1.2. Manufacture of crude active substance
- 3.1.3. Salt formation / Purification steps: Crystallisation

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via dol Tritone, n° 181 - 90187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenzigfarmeco.it
SIS: 1749

PC GMP





	2
3.5	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3.1 .	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystallisation
3.54 M	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of th
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
n e . 1 143703	Quality Control Testing
DS.D 13000 20	

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +390659784489
Fax +390659784312
website: www.agenziafarmaco.it
SIS: 1749





3 - Manufacturing	Operations - Active Substances
LEVOSULPIRIDE	
3.1 Man	ufacture of Active Substance by Chemical Synthesis
3.1.2	. Manufacture of crude active substance
3.1.3	. Salt formation /Purification steps:
	crystallisation
3.5 Gen	eral Finishing Steps
3.5.1	. Physical processing steps
	Drying, sieving, milling/micronisation
	4. Primary Packaging (enclosing / sealing the active substance within a
	aging material which is in direct contact with the substance)
	3. Secondary Packaging (placing the sealed primary package within an
	r packaging material or container. This also includes any labelling of the
	erial which could be used for identification or traceability (lot
num	bering) of the active substance)
3.6 Qua	lity Control Testing
3.6.3	L. Physical / Chemical testing

3 - Manufacturir LURASIDONE HY	g Operations - Active Substances
	nufacture of Active Substance by Chemical Synthesis
1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	1. Manufacture of active substance intermediates
3.1	.2. Manufacture of crude active substance
3.1	.3. Salt formation / Purification steps:
	crystallisation
3.5 Ge	neral Finishing Steps
3.5	.1. Physical processing steps
	drying, sieving, milling/micronisation
	.2. Primary Packaging (enclosing / sealing the active substance within a
	kaging material which is in direct contact with the substance)
∑ ` 3.5	.3. Secondary Packaging (placing the sealed primary package within an
[5] ou	ter packaging material or container. This also includes any labelling of the
∰/ ma	terial which could be used for identification or traceability (lot
ոս	mbering) of the active substance)

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (FFALY)
Tel.+390659784489 Fax +390559784312
website: www.agenziafarmaco.it
GIS: 1749







3.6 Qualit	Control esting
3.6.1.	Physical / Chemical testing


MEMANTII	acturing Operations - Active Substances NE HYDROCHLORIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystailisation
3.5 //4.000	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quanty Control Testing
	3.6.1. Physical / Chemical testing

3.1 N	Vlanuf 3.1.1.	NE HYDROCHLORIDE acture of Active Substance by Chemical Synthesis Manufacture of active substance intermediates
3	3.1.1.	Manufacture of active substance intermediates
3	3.1.1.	Manufacture of active substance intermediates
3	1.1.2.	
		Manufacture of crude active substance
3	3.1.3.	Salt formation / Purification steps:
		Crystallisation
3.5 G	Genera	il Finishing Steps
3(2)	3,5,1.	Physical processing steps
) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Drying, sieving, milling/micronisation
³ / (€) 3	3.5.2.	Primary Packaging (enclosing / scaling the active substance within a
1 € p	oackag	ing material which is in direct contact with the substance)

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312
website: www.agenziafarmsco.it
SIS: 1749



Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017 Document: SMF-001 Vers. 13



3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

Quality Control Testing

3.6.1. Physical / Chemical testing

3 - Manufacturing	Operations - Active Substances
	HYDROGEN OXALATE
3.1 Man	ufacture of Active Substance by Chemical Synthesis
3.1.3	. Manufacture of active substance intermediates
3.1.2	. Manufacture of crude active substance
3.1.3	Solt formation / Purification steps:
	Crystallisation
3.5 Gen	eral Finishing Steps
3.5.1	. Physical processing steps
	Drying, sleving, milling/micronisation
3.5.2	 Primary Packaging (enclosing / sealing the active substance within a
pack	aging material which is in direct contact with the substance)
3.5.3	3. Secondary Packaging (placing the sealed primary package within an
oute	r packaging material or container. This also includes any labelling of the
	erial which could be used for identification or traceability (lot
	bering) of the active substance)
	Ifty Control Testing
3.6.	Physical / Chemical testing

3 - Manufacturing Operations - Active Substances NAFTOPIDIL

Manufacture of Active Substance by Chemical Synthesis 3.1.1. Manufacture of active substance intermediates 3.1.2. Manufacture of crude active substance 3.1.3. Salt formation / Purification steps:

Crystallisation

AIFA Italian Medicines Agoncy
Manufacturing Authorization Office
Via dol Tritone, n° 181 - 00187 ROMA (ITALY)
T-1 - 20065978489
Fax +390659784312 website; www.agchziafarmaco.it SIS: 1749

PC GMP





3.5 Gener	rel Finishing Steps
3.5.1.	Physical processing steps
	Drying, sieving, milling/micronisation
3.5.2.	Primary Packaging (enclosing / sealing the active substance within a
раска	ging material which is in direct contact with the substance)
3,5,3.	Secondary Packaging (placing the sealed primary package within an
	packaging material or container. This also includes any labelling of the
mater	rial which could be used for identification or traceability (lot
numb	ering) of the active substance)
3.6 Quali	ty Control Testing
21 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	Physical / Chemical testing

3 - Manui	facturing Operations - Active Substances
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1.
	3.1.2.
	3.1.3.
3.5 % (2.2)	General Finishing Steps
	3.5.1.
	3.5.2.
	3.5.3.
3,6	Quality Control Testing:
	3.6.1.

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Vis del Tritons, n° 181 - 00187 ROMA (ITALY)
Tel.+390859784489 Fax +390859784312
website: www.agenziafarmaco.it
SIS: 1749

Page 15

Document: SMF-001 Vers. 13 Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017





3 - Manufact	turing Operations - Active Substances
ORPHENADR	RINE CITRATE
3,1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
1	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3,6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances		
ORPHENADRINE F	ORPHENADRINE HYDROCHLORIDE	
3.1 Man	ufacture of Active Substance by Chemical Synthesis	
3.1.1	. Manufacture of active substance intermediates	
3.1.2	L. Manufacture of crude active substance	
3.1.3	3. Salt formation / Purification steps:	
	Crystallisation	
3.5 Gen	eral Finishing Steps	
3,5.3	L. Physical processing steps	
	Drying, sieving, milling/micronisation	
	 Primary Packaging (enclosing / sealing the active substance within a 	
pack	aging material which is in direct contact with the substance)	
(⊅\ 3.5.3	3. Secondary Packaging (placing the sealed primary package within an	
	n packaging material or container. This also includes any labelling of the	
mate	erial which could be used for identification or traceability (lot	

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Visidel Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+890859784486 Fax +390859784312
website: www.agenziafarmeco.il
SIS: 1749



197



numbering) of the active substance)	
Quality Control Testing	ć
3.6.1. Physical / Chemical testing	

3 - Manufacturing Operations - Active Substances PYRIDOSTIGMINE BROMIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:
	Crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps
	Drying, sleving, milling/micronisation
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances PROPAFENONE HYDROCHLORIDE		
3.1	Manuf	acture of Active Substance by Chemical Synthesis
	3.1.1.	Manufacture of active substance intermediates
	3.1.2.	Manufacture of crude active substance
	3.1.3.	Salt formation / Purification steps:
		Crystallisation
3.5	Gener	al Finishing Steps
	3.5.1.	Physical processing steps
.		Drying, sieving, milling/micronisation
	3.5.2.	Primary Packaging (enclosing / sealing the active substance within a

CAIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tet.+39065978489
Fex.+390659784312
website: website: www.agenzlafarmaco.il
SIS: 1749



TO ASSET



AI/A

packaging material which is in direct contact with the substance)

3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

Outling Control Testing

3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances	
RANOLAZINE	
3.1	anufacture of Active Substance by Chemical Synthesis
3.:	1.1. Manufacture of active substance intermediates
3.3	1.2. Manufacture of crude active substance
3.:	1.3. Salt formation / Purification steps:
	Crystallisation
3,5	eneral Finishing Steps
3.5	5.1. Physical processing steps
	Drying, sieving, milling/micronisation
	5.2. Primary Packaging (enclosing / sealing the active substance within a
	ackaging material which is in direct contact with the substance)
	5.3. Secondary Packaging (placing the sealed primary package within an
	ater packaging material or container. This also includes any labelling of the
m	aterial which could be used for identification or traceability (lot
l Int	umbering) of the active substance)
3,6 Q	uality Control Lesting
3.	6.1. Physical / Chemical testing



3 - Manufacturing Operations - Active Substances SIVELESTAT SODIUM TETRAHYDRATE

Manufacture of Active Substance by Chemical Synthesis

- **3.1.1.** Manufacture of active substance intermediates
- 3.1.2. Manufacture of crude active substance
- 3.1.3. Salt formation / Purification steps: Crystallisation

AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tet.+390659784489
Fax +390659784312
website: www.aygnzjafarmaco.it
SIS: 1748

PC GMP

18 of 19

Document: SMF-001 Vers. 13 Attachment 3 Vers. 3 Effective date 11th December 2014 Expiry Date: 11th December 2017





3.5)	General Finisijing Steps
	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
1	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
]	packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an
	outer packaging material or container. This also includes any labelling of the
	material which could be used for identification or traceability (lot
	numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances	
TROSPIUM CHLORIDE	
	Manufacture of Active Substance by Chemical Synthesis
3	1.1.1. Manufacture of active substance intermediates
3	1.1.2. Manufacture of crude active substance
3	1.1.3. Salt formation / Purification steps:
	Crystallisation
3.5	eneral Finishing Steps
3	3.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
3	3.5.2. Primary Packaging (enclosing / sealing the active substance within a
p	packaging material which is in direct contact with the substance)
j 3	3.5.3. Secondary Packaging (placing the sealed primary package within an
i	outer packaging material or container. This also includes any labelling of the
n	naterial which could be used for identification or traceability (lot
n	numbering) of the active substance)
3.6	Quality Control Testing
3	8.6.1. Physical / Chemical testing



AIFA Italian Medicines Agency
Manufacturing Authorization Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel.+390659784489
Fax +390659784312
website: www agenziafsrmaco.it
SIS: 1749

PC GMP

..





3 - Manufacturing Operations - Active Substances	
TUAMINOHEPTANE SULFATE	
3.1. N	Nanufacture of Active Substance by Chemical Synthesis
3	.1.1. Manufacture of active substance intermediates
3	.1.2. Manufacture of crude active substance
з	.1.3. Salt formation / Purification steps:
	Crystallisation
3.5 G	eneral Finishing Steps
3	.5.1. Physical processing steps
	Drying, sieving, milling/micronisation
3	.5.2. Primary Packaging (enclosing / sealing the active substance within a
P	ackaging material which is in direct contact with the substance)
3	.5.3. Secondary Packaging (placing the sealed primary package within an
•	uter packaging material or container. This also includes any labelling of the
n	naterial which could be used for identification or traceability (lot
n	numbering) of the active substance)
3.6	Quality Control Testing
3	.6.1. Physical / Chemical testing

Restrictions or clarifying remarks:

Manufactured APIs marked as confidential are for clinical use only.

Rome, 10/21/2014



Name and signature of the authorised person of the Competent Authority of Republic of Italy

Dott, Renato Massimi AIFA - Manufacturing Authorization Office



AIFA Italian Medicines Agency
Manufacturing Authorization Offica
Via del Tritono, n° 181 - 90187 ROMA (ITALY)
Tel.+390659784489 Fax +390659784312 websito: www.agenziatarrnzco.if SIS: 1749

PC GMP